Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

[1]  B. Karlan,et al.  Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Raine-Bennett,et al.  Risk Management Options Elected by Women After Testing Positive for a BRCA Mutation , 2014 .

[3]  U. Menon,et al.  Ovarian cancer screening—Current status, future directions☆ , 2014, Gynecologic oncology.

[4]  J. Hopper,et al.  Preventing breast and ovarian cancers in high‐risk BRCA1 and BRCA2 mutation carriers , 2013, The Medical journal of Australia.

[5]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. , 2013, JAMA internal medicine.

[6]  C. Isaacs,et al.  Long‐term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance , 2012, Cancer.

[7]  S. Miller,et al.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2012 .

[8]  Nina Ditsch,et al.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. , 2011, Deutsches Arzteblatt international.

[9]  Tao Wang,et al.  Genetic testing and cancer risk management recommendations by physicians for at-risk relatives , 2011, Genetics in Medicine.

[10]  H. Gevensleben,et al.  Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers , 2011, Archives of Gynecology and Obstetrics.

[11]  Suzanne M. Miller,et al.  New Strategies in Ovarian Cancer: Uptake and Experience of Women at High Risk of Ovarian Cancer Who Are Considering Risk-Reducing Salpingo-Oophorectomy , 2010, Clinical Cancer Research.

[12]  M. Castiglione,et al.  BRCA in breast cancer: ESMO Clinical Practice Guidelines. , 2010, Annals of Oncology.

[13]  D. Morgan,et al.  Perceptions of High-Risk Care and Barriers to Care Among Women at Risk for Hereditary Breast and Ovarian Cancer following Genetic Counseling in the Community Setting , 2010, Journal of Genetic Counseling.

[14]  D. Morgan,et al.  Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting , 2009, Familial Cancer.

[15]  Gynecologists.  ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. , 2009, Obstetrics and gynecology.

[16]  E. Vittinghoff,et al.  Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. , 2009, Genetic testing and molecular biomarkers.

[17]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[18]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Couch,et al.  Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. , 2007, Clinical breast cancer.

[20]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Eeles,et al.  Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up , 2007, British Journal of Cancer.

[22]  N. Aaronson,et al.  Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[24]  T. Rebbeck,et al.  Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  S. Narod,et al.  The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation , 2005, Familial Cancer.

[26]  R. Eeles,et al.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort , 2004, British Journal of Cancer.

[27]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[28]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[29]  S. Mahon.  Factors affecting genetic testing and decisions about prophylactic surgery. , 2001, Clinical journal of oncology nursing.